Adults hospitalized for acute COPD exacerbation faced elevated odds for all-cause mortality and ICU admission if they had end-stage renal disease and were on dialysis, according to data presented at ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

The findings of three retrospective studies provide valuable insights into the burden of bronchiectasis across different ...

A tool combining CV risk score (CVRS) and coronary artery calcium score (CACS) facilitates stratification of patients with COPD at risk for MACE.

Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both ...

Each year, the European Lung Foundation (ELF) recognises outstanding research that advances patient-centred care and promotes ...

Recruitment ongoing for Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD; expect to report topline data from both studies in 1H26 - - New Drug Application for rademikibart ...

COPD emerged as an umbrella term for several respiratory diseases, including emphysema and chronic bronchitis, caused by lung damage. Because its effects are irreversible, early diagnosis and ...

Connect Biopharma Holdings Limited ( CNTB) Discusses Development Strategy for Next-Generation Biologic Targeting Acute and Chronic Respiratory Diseases November 3, 2025 4:15 PM EST ...

Luscii's Jonathan Lewis shares how live patient data, integrated into shared care and population health, could unlock ...

CHICAGO — Hospital volume affected the length of stay for patients with COPD who elect to have endobronchial valve placement, with some association with costs as well, according to an abstract ...